Glenn Freed
Gastroenterology · Pottsville, PANPI 1407841067
Payments from drug & device makers
Across 395 payments — averaging $9730.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2.2M
- Eli Lilly$1.2M
- Bristol Myers Squibb$271K
- AbbVie$199K
- Novo Nordisk AS$28K
- Alnylam Pharmaceuticals Inc.$9K
- plus $15K from 17 others
Across 6 payments — averaging $4161.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$25K
What the payments were for
- Food & beverage$2,15094%
- Education$673%
- Gifts$733%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer(2 entities) | 12 | $2,160,823 |
| Eli Lilly | 49 | $1,160,348 |
| Bristol Myers Squibb | 15 | $271,416 |
| AbbVie(2 entities) | 36 | $199,324 |
| Novo Nordisk AS | 163 | $27,646 |
| Alnylam Pharmaceuticals Inc. | 4 | $9,211 |
| E.r. Squibb & Sons, L.L.C. | 1 | $6,676 |
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $6,435 |
| Johnson & Johnson(2 entities) | 33 | $705 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $231 |
| Braintree Laboratories, Inc. | 4 | $131 |
| Gilead | 4 | $84 |
| Merck | 5 | $84 |
| Amarin Pharma, Inc. | 1 | $56 |
| Redhill Biopharma Inc. | 3 | $49 |
| AstraZeneca | 1 | $49 |
| Alfasigma USA, Inc. | 2 | $40 |
| Boston Scientific | 2 | $32 |
| Intercept Pharmaceuticals, Inc. | 2 | $32 |
| UCB, Inc. | 1 | $30 |
| Biofire Diagnostics, LLC | 1 | $21 |
| Pacira Pharmaceuticals Incorporated | 1 | $11 |
| Novo Nordisk | 1 | $11 |
How this compares
$3,843,446 in reported general payments places this provider in the 95th percentile of 935 gastroenterology providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntyvioVedolizumab | 22 | $199,222 |
| Dupixent PenDupilumab | 14 | $123,534 |
| Humira(Cf) PenAdalimumab | 14 | $93,572 |
| Mesalamine | 14 | $5,275 |
| Colestipol Hcl | 11 | $904 |
| Pantoprazole Sodium | 28 | $468 |
| Omeprazole | 32 | $283 |
| Metoclopramide Hcl | 13 | $106 |
| Sodium Chloride0.9 % Sodium Chloride | 14 | $59 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $6,435 | $199,22222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 935 gastroenterology providers in Pennsylvania.
Other gastroenterology in Pottsville
- Kuchikala ReddyPhiladelphia$6.5M
- Nirav ShahWyomissing$3.5M
- Jaideep BehariPittsburgh$2.7M
- Adnan AhmadCamp Hill$2.1M
- Frederick RuthardtUniontown$1.7M
- Adam PeytonAllentown$1.6M
- Dina Halegoua de MarzioPhiladelphia$1.5M
- Miguel RegueiroPittsburgh$1.5M
- Gary FalkPhiladelphia$1.4M
- Kristle LynchPhiladelphia$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.